dc.contributor.author
Bentanachs Raset, Roger
dc.contributor.author
Miró Martí, Ma. Lluïsa
dc.contributor.author
Ramírez-Carrasco, Patricia
dc.contributor.author
Sánchez, Rosa María
dc.contributor.author
Bernabeu Lorenzo, Manuel
dc.contributor.author
Amat, Concepció
dc.contributor.author
Alegret i Jordà, Marta
dc.contributor.author
Pérez Bosque, Anna
dc.contributor.author
Roglans i Ribas, Núria
dc.contributor.author
Laguna Egea, Juan Carlos
dc.date.accessioned
2026-01-17T20:31:13Z
dc.date.available
2026-01-17T20:31:13Z
dc.date.issued
2026-01-16T08:36:03Z
dc.date.issued
2026-01-16T08:36:03Z
dc.date.issued
2025-04-14
dc.date.issued
2026-01-16T08:36:03Z
dc.identifier
https://hdl.handle.net/2445/225599
dc.identifier.uri
http://hdl.handle.net/2445/225599
dc.description.abstract
In the present work, we analyse stored liver, adipose tissue (perigonadal</p><p>and brown), serum and faecal samples from our previous study and present new</p><p>biochemical, faecal metabolomic and microbiome data.</p><p>We show that oral administration of mirabegron</p><p>significantly increases the expression of uncoupling protein 1 in brown</p><p>adipose tissue and β3-Adrenergic receptor protein in perigonadal white</p><p>adipose and liver tissues. Furthermore, mirabegron treatment changes the</p><p>relative abundance of several genus and families of rat faecal microbiota,</p><p>albeit without restoring the global biodiversity and evenness indexes observed</p><p>in control rats, as well as faecal bile acids composition. These changes are</p><p>probably due to a direct effect of mirabegron on the gut microbiome, rather</p><p>than being mediated by changes in bile acid induced by drug treatment.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fphar.2025.1547749
dc.relation
Frontiers in Pharmacology, 2025
dc.relation
https://doi.org/10.3389/fphar.2025.1547749
dc.rights
cc-by (c) Bentanachs, R. et al., 2025
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Malalties del fetge
dc.subject
Liver diseases
dc.subject
Adipose tissues
dc.title
Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion